Status:
UNKNOWN
Treatment of Leukemia and Lymphoma in Children With Ataxia Telangiectasia
Lead Sponsor:
Rabin Medical Center
Collaborating Sponsors:
Israeli Society for Pediatric Hematology-Oncology
International BFM Study Group
Conditions:
Ataxia Telangiectasia
Leukemia
Eligibility:
All Genders
Up to 21 years
Brief Summary
Ataxia telangiectasia (A-T) is a multisystem disease with diverse manifestations, including progressive neurodegeneration, immunodeficiency, respiratory disease, and genomic instability. One of the mo...
Detailed Description
Ataxia telangiectasia (A-T) is a multisystem disease with diverse manifestations, including progressive neurodegeneration, immunodeficiency, respiratory disease, and genomic instability. A-T is caused...
Eligibility Criteria
Inclusion
- Individuals diagnosed with ataxia telangiectasia and leukemia or lymphoma
- Age 0-21
Exclusion
- Age greater than 21 years
Key Trial Info
Start Date :
July 28 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 30 2021
Estimated Enrollment :
250 Patients enrolled
Trial Details
Trial ID
NCT04037189
Start Date
July 28 2019
End Date
December 30 2021
Last Update
October 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schneider Children's Medical Center
Petah Tikva, Israel, 4920235